Loading prototype

ACTS Demo

Recommendation summary: STRENGTH:
Conclusion:
Recommendations Clinical questions Studies Open in marketplace
For COVID Patients In:Critical CareHospitalized (not critical)Outpatient
ASH Recommends:Suggests using prophylactic-intensity anticoagulation
Strength: conditional recommendation - DRAFT RECOMMENDATION
Last review date: 2021-04-07
Prophylactic-intensity over DOACs, LMWH, UFH, Fondaparinux, Argatroban, or Bivalirudin at intermediate-intensity or therapeutic-intensity
Strength: weak
Last review date: 2020-10-26
Suggests NOT using anticoagulant outpatient thromboprophylaxis after hospital discharge
Strength: conditional recommendation - DRAFT RECOMMENDATION
Last review date: 2021-07-08
NIH Recommends:Provide prophylactic dose anticoagulation
Strength: AIII
Last review date: 2021-02-11
Provide prophylactic dose anticoagulation
Strength: AIII
Last review date: 2021-02-11
Do NOT initiate prophylactic anticoagulation or antiplatelet therapy
Strength: AIII
Last review date: 2021-02-11
WHO Recommends:Anticoagulation at prophylactic intensity
Strength: weak
Last review date: 2021-01-25
Anticoagulation at prophylactic intensity
Strength: weak
Last review date: 2021-01-25

Australian Guidelines Recommends:Use prophylactic doses of anticoagulants, preferably low molecular weight heparin (LMWH)
Strength: Conditional recommendation
Last review date: 2021-07-14
Do not routinely offer therapeutic anticoagulant dosing
Strength: weak